DK0638121T3 - Målrettet spaltning af RNA under anvendelse af eukaryotisk ribonuklease P og ekstern ledersekvens - Google Patents

Målrettet spaltning af RNA under anvendelse af eukaryotisk ribonuklease P og ekstern ledersekvens

Info

Publication number
DK0638121T3
DK0638121T3 DK93910848.6T DK93910848T DK0638121T3 DK 0638121 T3 DK0638121 T3 DK 0638121T3 DK 93910848 T DK93910848 T DK 93910848T DK 0638121 T3 DK0638121 T3 DK 0638121T3
Authority
DK
Denmark
Prior art keywords
egs
rna
rnaase
cleavage
loop
Prior art date
Application number
DK93910848.6T
Other languages
English (en)
Inventor
Yan Yuan
Cecilia L Guerrier-Takada
Sidney Altman
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Application granted granted Critical
Publication of DK0638121T3 publication Critical patent/DK0638121T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/126—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes involving RNAse P

Landscapes

  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DK93910848.6T 1992-04-28 1993-04-28 Målrettet spaltning af RNA under anvendelse af eukaryotisk ribonuklease P og ekstern ledersekvens DK0638121T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87509992A 1992-04-28 1992-04-28
US93193792A 1992-08-18 1992-08-18

Publications (1)

Publication Number Publication Date
DK0638121T3 true DK0638121T3 (da) 1996-08-12

Family

ID=27128368

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93910848.6T DK0638121T3 (da) 1992-04-28 1993-04-28 Målrettet spaltning af RNA under anvendelse af eukaryotisk ribonuklease P og ekstern ledersekvens

Country Status (10)

Country Link
EP (1) EP0638121B1 (da)
JP (1) JP3015463B2 (da)
AT (1) ATE140482T1 (da)
AU (1) AU669367B2 (da)
CA (1) CA2117903C (da)
DE (1) DE69303712T2 (da)
DK (1) DK0638121T3 (da)
ES (1) ES2093427T3 (da)
GR (1) GR3020859T3 (da)
WO (1) WO1993022434A2 (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869248A (en) * 1994-03-07 1999-02-09 Yale University Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
US5683873A (en) * 1995-01-13 1997-11-04 Innovir Laboratories, Inc. EGS-mediated inactivation of target RNA
US6057153A (en) * 1995-01-13 2000-05-02 Yale University Stabilized external guide sequences
US5877162A (en) * 1996-03-14 1999-03-02 Innovir Laboratories, Inc. Short external guide sequences
US6610478B1 (en) 1996-08-16 2003-08-26 Yale University Phenotypic conversion of cells mediated by external guide sequences
WO1999027135A2 (en) * 1997-11-21 1999-06-03 Yale University Method for identifying and inhibiting functional nucleic acid molecules in cells
US6013447A (en) * 1997-11-21 2000-01-11 Innovir Laboratories, Inc. Random intracellular method for obtaining optimally active nucleic acid molecules
US6248525B1 (en) 1998-03-30 2001-06-19 Yale University Method for identifying essential or functional genes
CA2425779C (en) 2000-10-12 2013-08-06 University Of Rochester Compositions that inhibit proliferation of cancer cells
BR0307470A (pt) 2002-02-06 2006-12-19 Vicor Technologies Inc fração de plasma de um animal hibernante e métodos de purificar uma molécula tendo atividade anti-infarto, de reduzir um infarto em um indivìduo de produzir e de identificar uma molécula anti-infarto e de identificar um inibidor da interação entre a bradicinina e o tipo 2 do receptor de angiotensina ii
US20050287648A1 (en) 2002-08-05 2005-12-29 University Of Rochester Protein Transducing Domain/Deaminase Chimeric Proteins, Related Compounds, and Uses Thereof
US9233120B2 (en) 2002-11-15 2016-01-12 Jyant Technologies Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration
US8658377B2 (en) 2002-11-15 2014-02-25 Morehouse School Of Medicine Detecting cancer with anti-CCL25 and anti-CCR9 antibodies
US8512701B2 (en) 2002-11-15 2013-08-20 Morehouse School Of Medicine Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration
CA2564988A1 (en) 2004-04-29 2005-10-29 Yale University Nuclease resistant external guide sequences for treating inflammatory and viral related respiratory diseases
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
US7964577B2 (en) 2005-10-14 2011-06-21 Donald Carlton D Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
US8470965B2 (en) 2006-03-01 2013-06-25 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
US9365622B2 (en) 2006-03-01 2016-06-14 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
US20100190689A1 (en) 2006-09-21 2010-07-29 University Of Rochester Compositions and methods related to protein displacement therapy for myotonic distrophy
US8999317B2 (en) 2006-11-01 2015-04-07 University Of Rochester Methods and compositions related to the structure and function of APOBEC3G
US9896511B2 (en) 2007-01-10 2018-02-20 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
CA2706317C (en) 2007-12-03 2017-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Doc1 compositions and methods for treating cancer
US9822364B2 (en) 2008-03-11 2017-11-21 Yale University Compositions and methods for controlled delivery of inhibitory ribonucleic acids
WO2009114614A2 (en) 2008-03-11 2009-09-17 Yale University Compositions and methods for controlled delivery of inhibitory ribonucleic acids
WO2009137686A1 (en) 2008-05-08 2009-11-12 University Of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
US20120070443A1 (en) 2008-12-02 2012-03-22 University Of Utah Research Foundation Pde1 as a target therapeutic in heart disease
US20110318738A1 (en) 2008-12-23 2011-12-29 University Of Utah Research Foundation Identification and regulation of a novel dna demethylase system
WO2010151638A1 (en) 2009-06-25 2010-12-29 Medical College Of Georgia Research Institute, Inc. Jnk inhibitors for use in treating spinal muscular atrophy
WO2011031974A1 (en) 2009-09-10 2011-03-17 Southern Research Institute Acridine analogs in the treatment of gliomas
US20110274745A1 (en) 2009-11-10 2011-11-10 Lipella Pharmaceuticals Inc. Instillation of liposomal formulation of sirna and antisense oligonucleotides
WO2011082231A1 (en) 2009-12-31 2011-07-07 New York University Compositions and methods for promoting epithelialization and wound closure
US20110207789A1 (en) 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
JP2014505239A (ja) 2010-12-14 2014-02-27 モアハウス スクール オブ メディスン 癌の治療または検出のための抗ｃｘｃｌ１３および抗ｃｘｃｒ５抗体の使用
KR20140104344A (ko) 2011-05-20 2014-08-28 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 시크리터리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비시스 Ｔ 세포 매개성 질병의 병증을 개선하기 위한 ｔｌ１ａ-ｄｒ３의 상호작용의 차단 및 그것의 항체
WO2013044116A1 (en) 2011-09-21 2013-03-28 Yale University Antimicrobial compositions and methods of use thereof
KR101343959B1 (ko) 2012-09-19 2013-12-24 한국기계연구원 통합 코팅 장치
CA2965952A1 (en) 2014-10-27 2016-05-06 University Of Central Florida Research Foundation, Inc. Methods and compositions for natural killer cells
EP3496736A4 (en) 2016-08-03 2020-05-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. THERAPEUTICS AGAINST TLR9
EP4060035A4 (en) * 2021-01-27 2023-01-25 CJ CheilJedang Corporation NEW VARIANT OF RIBONUCLEASE P, AND METHOD FOR PRODUCING L-GLUTAMIC ACID USING THE SAME

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
JP2750127B2 (ja) * 1988-07-29 1998-05-13 三共株式会社 リボザイムによるポリリボヌクレオチド特定部位の切断方法
US5168053A (en) * 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P

Also Published As

Publication number Publication date
AU4119893A (en) 1993-11-29
ATE140482T1 (de) 1996-08-15
WO1993022434A3 (en) 1993-12-23
ES2093427T3 (es) 1996-12-16
JP3015463B2 (ja) 2000-03-06
CA2117903C (en) 1999-01-12
AU669367B2 (en) 1996-06-06
CA2117903A1 (en) 1993-11-11
JPH07507683A (ja) 1995-08-31
EP0638121B1 (en) 1996-07-17
WO1993022434A2 (en) 1993-11-11
DE69303712T2 (de) 1997-02-20
DE69303712D1 (de) 1996-08-22
EP0638121A1 (en) 1995-02-15
GR3020859T3 (en) 1996-11-30

Similar Documents

Publication Publication Date Title
DK0638121T3 (da) Målrettet spaltning af RNA under anvendelse af eukaryotisk ribonuklease P og ekstern ledersekvens
DE69512219D1 (de) Gezielte spaltung von rns mittels gezielter bindung der ribonuklease p und spaltungssequenzen
AR245776A1 (es) Metodo para la modificacion de las caracteristicas de expresion de un gen endogeno de un microorganismo o una linea celular determinada.
DK1017803T3 (da) Ekspression af endogene gener ved ikke-homolog rekombination af et vektorkonstrukt med cellulært DNA
DK0941318T3 (da) Håndvægtformede konstruerede ekspressionssystemer til genterapi
ES2148323T3 (es) Sistema de expresion de un gen a base de geminivirus.
BR9914643A (pt) Vetores adeno-associados para expressão dofator viii por células alvo
CY1112430T1 (el) Λεντινοϊικο τριπλο dνα και οχηματα και ανασυνδυασμενα κυτταρα που περιεχουν λεντινοϊικο τριπλο dνα
EP2267138A3 (en) Methods and means for obtaining modified phenotypes
HUP0402164A2 (hu) Ellenanyagok policisztronos expresszáltatása
ES2153358T3 (es) Procedimientos para la seleccion de celulas huespedes recombinantes que expresan altos niveles de una proteina deseada.
DK1175489T3 (da) Oligonukleotider indeholdende en antisense-sekvens stabiliseret af en sekundær struktur og farmaceutiske præparater indeholdende disse oligonukleotider
WO1998037185A3 (en) Vectors for controlled gene expression
DK0843731T3 (da) Adenovirusvektorer til genterapi
Palese RNA virus vectors: where are we and where do we need to go?
WO1999061589A3 (en) Expansion of hematopoietic stem cells transduced with mdr-1 and methods of use thereof
MXPA02003422A (es) Alteracion de la expresion de genes con adnss producido in vivo.
DE3773512D1 (de) Vektor und verfahren zur erreichung einer hohen expression in zellen.
BR9712532A (pt) Método para aumentar o nìvel de expressão de um transgene população de células monocotiledÈneas,plantas e sementes
CO4790179A1 (es) Procedimiento para la fabricacion de proteinas humanas por activacion genica endogena
DE60124910D1 (de) Menschliche twik-8 moleküle und ihre verwendung
ATE419350T1 (de) Humanes trp-ähnliches kalziumkanalprotein-2 tlcc- 2
JPS6480281A (en) Plant cell and body
AU2001285204A1 (en) Atcr-1, a human acyltransferase and uses thereof
KR950025103A (ko) 신규 바이시스트로닉 벡터